Education
About Us
Working with TipRanks
Follow Us
Intervacc AB (DE:2E9)
:2E9
2E9 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EST
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€29.61M
Enterprise Value€182.17M
Total Cash (Recent Filing)€172.36M
Total Debt (Recent Filing)€78.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Feb 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.54
Price to Sales (P/S)7.49
P/FCF Ratio-1.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.02 and its highest was €0.16 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €29.61M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Feb 17, 2026 which is in 67 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on Nov 19, 2025. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.903%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
Company Description
Intervacc AB
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―